Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending.
Published By Datamonitor
|
24 Mar 2011 |
|
CommentWire
|
Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.
Published By Datamonitor
|
14 Oct 2010 |
|
CommentWire
|
Roche has announced that a Phase III trial for Avastin in early-stage colorectal cancer has failed to meet its primary endpoint. Although this setback is unlikely to affect Avastin's sales in its approved indications, it creates a commercially attractive opportunity for rival drug Erbitux to gain first-to-market status in early-stage colorectal cancer.
Published By Datamonitor
|
22 Apr 2009 |
|
CommentWire
|
Genentech has declined the $43.7 billion takeover bid made by Swiss pharmaceutical giant Roche, on the grounds that the offer undervalues the benefits that full-ownership of the US biotech would provide. Genentech's unsurprising decision leaves the door open to further negotiations, with a deal expected to be finalized within the next few months.
Published By Datamonitor
|
14 Aug 2008 |
|
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
Expert View
|
Novartis has agreed to acquire a controlling stake in ophthalmology specialist Alcon for around $39 billion, revealing a clear intention to drive diversification from its core prescription pharmaceutical business. Although Alcon will not come cheap, the acquisition represents a positive, long-term strategy by Novartis which faces intensifying generic competition over the next five years.
Published By Datamonitor
|
08 Apr 2008 |
|
CommentWire
|
After a number of setbacks in the first half of 2007, Novartis expects to return to "strong growth" by the second half of 2008 and to achieve double-digit growth between 2008 and 2011. With its rivals struggling to overcome the effects of heavy genericization, if the company achieves this level of growth, it will stand out as one of the fastest-growing players in the industry.
Published By Datamonitor
|
13 Sep 2007 |
|
CommentWire
|
Roche's $3 billion bid for the diagnostics specialist Ventana has been dismissed by the US company's board as "inadequate". Although the board states that the offer is not even high enough to warrant opening negotiations, the strategic attractiveness of the company to Roche is likely to prompt the Swiss pharma to return with an improved offer.
Published By Datamonitor
|
12 Jul 2007 |
|
CommentWire
|
The latest Phase III study results for Actemra confirm previous findings that the drug is a safe and effective biologic therapy for rheumatoid arthritis sufferers. In particular, Actemra will be a therapy for niche rheumatoid arthritis patients who do not adequately respond to anti-TNF or traditional disease-modifying drugs, further strengthening the immunology franchise of Roche and Chugai.
Published By Datamonitor
|
12 Jul 2007 |
|
CommentWire
|
Thanks to a new deal with Intercell, Novartis is set to gain access to several vaccine candidates, including those for the prevention of pneumonia in elderly and infants, and hospital-acquired Pseudomonas. After several agreements with other companies and the acquisition of Chiron in 2006, it appears Novartis is on its way to becoming a major infectious diseases player.
Published By Datamonitor
|
02 Jul 2007 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.